70 related articles for article (PubMed ID: 15650456)
1. Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer.
El-Mabhouh A; Angelov C; McEwan A; Jia G; Mercer J
Cancer Biother Radiopharm; 2004 Oct; 19(5):627-40. PubMed ID: 15650456
[TBL] [Abstract][Full Text] [Related]
2. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases.
El-Mabhouh A; Mercer JR
Appl Radiat Isot; 2005 Apr; 62(4):541-9. PubMed ID: 15701408
[TBL] [Abstract][Full Text] [Related]
3. In-vivo tissue uptake and retention of Sn-117m(4+)DTPA in a human subject with metastatic bone pain and in normal mice.
Swailem FM; Krishnamurthy GT; Srivastava SC; Aguirre ML; Ellerson DL; Walsh TK; Simpson L; Shah J
Nucl Med Biol; 1998 Apr; 25(3):279-87. PubMed ID: 9620634
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate.
Hosain F; Spencer RP; Couthon HM; Sturtz GL
J Nucl Med; 1996 Jan; 37(1):105-7. PubMed ID: 8543977
[TBL] [Abstract][Full Text] [Related]
5. A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer.
El-Mabhouh AA; Angelov CA; Cavell R; Mercer JR
Nucl Med Biol; 2006 Aug; 33(6):715-22. PubMed ID: 16934690
[TBL] [Abstract][Full Text] [Related]
6. A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases.
El-Mabhouh AA; Nation PN; Abele JT; Riauka T; Postema E; McEwan AJ; Mercer JR
Oncol Res; 2011; 19(6):287-95. PubMed ID: 21776824
[TBL] [Abstract][Full Text] [Related]
7. Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain.
Krishnamurthy GT; Swailem FM; Srivastava SC; Atkins HL; Simpson LJ; Walsh TK; Ahmann FR; Meinken GE; Shah JH
J Nucl Med; 1997 Feb; 38(2):230-7. PubMed ID: 9025743
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer.
Mbese Z; Aderibigbe BA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206757
[TBL] [Abstract][Full Text] [Related]
10. Studies on the synthesis and biological properties of non-carrier-added [(125)I and (131)I]-labeled arylalkylidenebisphosphonates: potent bone-seekers for diagnosis and therapy of malignant osseous lesions.
Arstad E; Hoff P; Skattebøl L; Skretting A; Breistøl K
J Med Chem; 2003 Jul; 46(14):3021-32. PubMed ID: 12825941
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.
Schott S; Vallet S; Tower RJ; Noor S; Tiwari S; Schem C; Busch C
Invest New Drugs; 2015 Aug; 33(4):816-26. PubMed ID: 25986684
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.
van Beek ER; Lowik CW; van Wijngaarden J; Ebetino FH; Papapoulos SE
Breast Cancer Res Treat; 2009 Nov; 118(2):307-13. PubMed ID: 18989771
[TBL] [Abstract][Full Text] [Related]
13. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
Larsen RH; Murud KM; Akabani G; Hoff P; Bruland OS; Zalutsky MR
J Nucl Med; 1999 Jul; 40(7):1197-203. PubMed ID: 10405142
[TBL] [Abstract][Full Text] [Related]
14. Technetium-99m labeled agents for skeletal imaging.
Thrall JH
CRC Crit Rev Clin Radiol Nucl Med; 1976; 8(1):1-31. PubMed ID: 789010
[TBL] [Abstract][Full Text] [Related]
15. On the horizon: can bisphosphonates prevent bone metastases?
Coleman R
Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
17. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
Kumar V; Kumar D; Howman-Giles RB; Little DG
Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of bisphosphonate compound labeled with (99m)Tc(CO)3(+).
Şenocak K; Teksöz S; İçhedef Ç; Uçar E
Chem Biol Drug Des; 2015 Mar; 85(3):369-76. PubMed ID: 25092179
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates in oncology.
Coleman RE; McCloskey EV
Bone; 2011 Jul; 49(1):71-6. PubMed ID: 21320652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
